Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 4411 entries
Sorted by: Best Match Show Resources per page
Relapsed angioimmunoblastic T-cell lymphoma with acquired expression of CD20: a case report and review of the literature.

BMC clinical pathology

Banz Y, Krasniqi F, Dirnhofer S, Tzankov A.
PMID: 23738899
BMC Clin Pathol. 2013 Jun 05;13:18. doi: 10.1186/1472-6890-13-18.

BACKGROUND: Angioimmunoblastic T-cell lymphoma is one of the most common types of peripheral T-cell lymphomas, usually presenting at an older age with an aggressive clinical course. Its characteristic morphological presentation and follicular helper T-cell phenotype help to distinguish it...

Cite
Banz Y, Krasniqi F, Dirnhofer S, et al. Relapsed angioimmunoblastic T-cell lymphoma with acquired expression of CD20: a case report and review of the literature. BMC Clin Pathol. 2013;13:18doi: 10.1186/1472-6890-13-18.
Banz, Y., Krasniqi, F., Dirnhofer, S., & Tzankov, A. (2013). Relapsed angioimmunoblastic T-cell lymphoma with acquired expression of CD20: a case report and review of the literature. BMC clinical pathology, 1318. https://doi.org/10.1186/1472-6890-13-18
Banz, Yara, et al. "Relapsed angioimmunoblastic T-cell lymphoma with acquired expression of CD20: a case report and review of the literature." BMC clinical pathology vol. 13 (2013): 18. doi: https://doi.org/10.1186/1472-6890-13-18
Banz Y, Krasniqi F, Dirnhofer S, Tzankov A. Relapsed angioimmunoblastic T-cell lymphoma with acquired expression of CD20: a case report and review of the literature. BMC Clin Pathol. 2013 Jun 05;13:18. doi: 10.1186/1472-6890-13-18. PMID: 23738899; PMCID: PMC3680012.
Copy Download .nbib Format: NLM
A rare tumor with unusual clinical presentation detected by positron emission tomography-computed tomography.

Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India

Patel SK, Shera IA.
PMID: 26430318
Indian J Nucl Med. 2015 Oct-Dec;30(4):331-3. doi: 10.4103/0972-3919.164024.

Primary hepatic lymphoma represents

Cite
Patel SK, Shera IA. A rare tumor with unusual clinical presentation detected by positron emission tomography-computed tomography. Indian J Nucl Med. 2015;30(4):331-3doi: 10.4103/0972-3919.164024.
Patel, S. K., & Shera, I. A. (2015). A rare tumor with unusual clinical presentation detected by positron emission tomography-computed tomography. Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India, 30(4), 331-3. https://doi.org/10.4103/0972-3919.164024
Patel, Sitendu Kumar, and Shera, Irfan Ali. "A rare tumor with unusual clinical presentation detected by positron emission tomography-computed tomography." Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India vol. 30,4 (2015): 331-3. doi: https://doi.org/10.4103/0972-3919.164024
Patel SK, Shera IA. A rare tumor with unusual clinical presentation detected by positron emission tomography-computed tomography. Indian J Nucl Med. 2015 Oct-Dec;30(4):331-3. doi: 10.4103/0972-3919.164024. PMID: 26430318; PMCID: PMC4579619.
Copy Download .nbib Format: NLM
Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.

Therapeutic advances in neurological disorders

Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG.
PMID: 28450895
Ther Adv Neurol Disord. 2017 Jan;10(1):51-66. doi: 10.1177/1756285616666741. Epub 2016 Sep 02.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that is caused by an autoimmune response against central nervous system (CNS) structures. Traditionally considered a T-cell-mediated disorder, the contribution of B cells to the pathogenesis of MS has long...

Cite
Bittner S, Ruck T, Wiendl H, et al. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2016;10(1):51-66doi: 10.1177/1756285616666741.
Bittner, S., Ruck, T., Wiendl, H., Grauer, O. M., & Meuth, S. G. (2017). Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Therapeutic advances in neurological disorders, 10(1), 51-66. https://doi.org/10.1177/1756285616666741
Bittner, Stefan, et al. "Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management." Therapeutic advances in neurological disorders vol. 10,1 (2017): 51-66. doi: https://doi.org/10.1177/1756285616666741
Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017 Jan;10(1):51-66. doi: 10.1177/1756285616666741. Epub 2016 Sep 02. PMID: 28450895; PMCID: PMC5400151.
Copy Download .nbib Format: NLM
Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

OncoTargets and therapy

Hill BT, Kalaycio M.
PMID: 26366093
Onco Targets Ther. 2015 Aug 31;8:2391-7. doi: 10.2147/OTT.S68770. eCollection 2015.

Chronic lymphocytic leukemia (CLL) is a hematologic malignancy derived from a clonal population of mature B-lymphocytes characterized by relatively low CD20 antigen expression. Although the disease often takes an indolent course, the majority of patients will eventually require therapy....

Cite
Hill BT, Kalaycio M. Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. Onco Targets Ther. 2015;8:2391-7doi: 10.2147/OTT.S68770.
Hill, B. T., & Kalaycio, M. (2015). Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. OncoTargets and therapy, 82391-7. https://doi.org/10.2147/OTT.S68770
Hill, Brian T, and Kalaycio, Matt. "Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia." OncoTargets and therapy vol. 8 (2015): 2391-7. doi: https://doi.org/10.2147/OTT.S68770
Hill BT, Kalaycio M. Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. Onco Targets Ther. 2015 Aug 31;8:2391-7. doi: 10.2147/OTT.S68770. eCollection 2015. PMID: 26366093; PMCID: PMC4562745.
Copy Download .nbib Format: NLM
Managing refractory cryoglobulinemic vasculitis: challenges and solutions.

Journal of inflammation research

Ostojic P, Jeremic IR.
PMID: 28507447
J Inflamm Res. 2017 May 08;10:49-54. doi: 10.2147/JIR.S114067. eCollection 2017.

Cryoglobulinemia is thought to be a rare condition. It may be an isolated disorder or secondary to a particular disease. According to immunoglobulin composition, cryoglobulinemia is classified into three types. In mixed cryoglobulinemia (types II and III), vascular deposition...

Cite
Ostojic P, Jeremic IR. Managing refractory cryoglobulinemic vasculitis: challenges and solutions. J Inflamm Res. 2017;10:49-54doi: 10.2147/JIR.S114067.
Ostojic, P., & Jeremic, I. R. (2017). Managing refractory cryoglobulinemic vasculitis: challenges and solutions. Journal of inflammation research, 1049-54. https://doi.org/10.2147/JIR.S114067
Ostojic, Predrag, and Jeremic, Ivan R. "Managing refractory cryoglobulinemic vasculitis: challenges and solutions." Journal of inflammation research vol. 10 (2017): 49-54. doi: https://doi.org/10.2147/JIR.S114067
Ostojic P, Jeremic IR. Managing refractory cryoglobulinemic vasculitis: challenges and solutions. J Inflamm Res. 2017 May 08;10:49-54. doi: 10.2147/JIR.S114067. eCollection 2017. PMID: 28507447; PMCID: PMC5428757.
Copy Download .nbib Format: NLM
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.

The Lancet. Haematology

Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, Marcheselli L, Berriolo-Riedinger A, Franceschetto A, Julian A, Ricard F, Guerra L, Haioun C, Biasoli I, Tilly H, Federico M, Salles G, Meignan M.
PMID: 27030064
Lancet Haematol. 2014 Oct;1(1):e17-27. doi: 10.1016/S2352-3026(14)70008-0. Epub 2014 Sep 17.

BACKGROUND: The value of (18)F-fluorodeoxyglucose (FDG) PET-CT (PET) imaging in response assessment after first-line rituximab chemotherapy for follicular lymphoma has been documented. We analysed the application of the five-point Deauville scale (5PS; used to score FDG uptake on PET...

Cite
Trotman J, Luminari S, Boussetta S, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014;1(1):e17-27doi: 10.1016/S2352-3026(14)70008-0.
Trotman, J., Luminari, S., Boussetta, S., Versari, A., Dupuis, J., Tychyj, C., Marcheselli, L., Berriolo-Riedinger, A., Franceschetto, A., Julian, A., Ricard, F., Guerra, L., Haioun, C., Biasoli, I., Tilly, H., Federico, M., Salles, G., & Meignan, M. (2014). Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. The Lancet. Haematology, 1(1), e17-27. https://doi.org/10.1016/S2352-3026(14)70008-0
Trotman, Judith, et al. "Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies." The Lancet. Haematology vol. 1,1 (2014): e17-27. doi: https://doi.org/10.1016/S2352-3026(14)70008-0
Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, Marcheselli L, Berriolo-Riedinger A, Franceschetto A, Julian A, Ricard F, Guerra L, Haioun C, Biasoli I, Tilly H, Federico M, Salles G, Meignan M. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014 Oct;1(1):e17-27. doi: 10.1016/S2352-3026(14)70008-0. Epub 2014 Sep 17. PMID: 27030064.
Copy Download .nbib Format: NLM
Lymphomatoid granulomatosis associated with azathioprine use for immune-mediated neuropathy.

BMJ case reports

Burwick N, Buckley SA, Dong ZM, Richard RE.
PMID: 27671987
BMJ Case Rep. 2016 Sep 26;2016. doi: 10.1136/bcr-2016-216930.

Lymphomatoid granulomatosis (LG) is a rare Epstein-Barr virus-driven lymphoproliferative disorder that generally arises in immunosuppressed patients and which can be life-threatening. Here we describe the development of pulmonary LG in a patient on long-term azathioprine for immune-mediated neuropathy. Although...

Cite
Burwick N, Buckley SA, Dong ZM, et al. Lymphomatoid granulomatosis associated with azathioprine use for immune-mediated neuropathy. BMJ Case Rep. 2016;2016doi: 10.1136/bcr-2016-216930.
Burwick, N., Buckley, S. A., Dong, Z. M., & Richard, R. E. (2016). Lymphomatoid granulomatosis associated with azathioprine use for immune-mediated neuropathy. BMJ case reports, 2016. https://doi.org/10.1136/bcr-2016-216930
Burwick, Nicholas, et al. "Lymphomatoid granulomatosis associated with azathioprine use for immune-mediated neuropathy." BMJ case reports vol. 2016 (2016). doi: https://doi.org/10.1136/bcr-2016-216930
Burwick N, Buckley SA, Dong ZM, Richard RE. Lymphomatoid granulomatosis associated with azathioprine use for immune-mediated neuropathy. BMJ Case Rep. 2016 Sep 26;2016. doi: 10.1136/bcr-2016-216930. PMID: 27671987; PMCID: PMC5051443.
Copy Download .nbib Format: NLM
Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab.

Scandinavian journal of rheumatology

Bellan M, Pirisi M, Sainaghi PP.
PMID: 26312648
Scand J Rheumatol. 2016 Jan;45(1):83-84. doi: 10.3109/03009742.2015.1058417. Epub 2015 Aug 31.

No abstract available.

Cite
Bellan M, Pirisi M, Sainaghi PP. Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab. Scand J Rheumatol. 2015;45(1):83-84doi: 10.3109/03009742.2015.1058417.
Bellan, M., Pirisi, M., & Sainaghi, P. P. (2016). Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab. Scandinavian journal of rheumatology, 45(1), 83-84. https://doi.org/10.3109/03009742.2015.1058417
Bellan, M, et al. "Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab." Scandinavian journal of rheumatology vol. 45,1 (2016): 83-84. doi: https://doi.org/10.3109/03009742.2015.1058417
Bellan M, Pirisi M, Sainaghi PP. Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab. Scand J Rheumatol. 2016 Jan;45(1):83-84. doi: 10.3109/03009742.2015.1058417. Epub 2015 Aug 31. PMID: 26312648.
Copy Download .nbib Format: NLM
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Oncoimmunology

Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M.
PMID: 26942070
Oncoimmunology. 2015 Jun 05;5(1):e1058459. doi: 10.1080/2162402X.2015.1058459. eCollection 2016.

Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated through the IgG Fc receptor FcγRIIIa represents a major effector function of many therapeutic antibodies. In an attempt to further enhance natural killer (NK) cell-mediated ADCC, we combined therapeutic antibodies against CD20 and CD38...

Cite
Kellner C, Günther A, Humpe A, et al. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology. 2015;5(1):e1058459doi: 10.1080/2162402X.2015.1058459.
Kellner, C., Günther, A., Humpe, A., Repp, R., Klausz, K., Derer, S., Valerius, T., Ritgen, M., Brüggemann, M., van de Winkel, J. G., Parren, P. W., Kneba, M., Gramatzki, M., & Peipp, M. (2016). Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology, 5(1), e1058459. https://doi.org/10.1080/2162402X.2015.1058459
Kellner, Christian, et al. "Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30." Oncoimmunology vol. 5,1 (2016): e1058459. doi: https://doi.org/10.1080/2162402X.2015.1058459
Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology. 2015 Jun 05;5(1):e1058459. doi: 10.1080/2162402X.2015.1058459. eCollection 2016. PMID: 26942070; PMCID: PMC4760288.
Copy Download .nbib Format: NLM
Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.

Transplantation direct

Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, Ten Berge IJ.
PMID: 27500242
Transplant Direct. 2015 Dec 15;2(1):e48. doi: 10.1097/TXD.0000000000000557. eCollection 2016 Jan.

Posttransplant lymphoproliferative disease (PTLD) is a potentially fatal complication after (solid organ) transplantation, which is highly associated with Epstein-Barr virus (EBV). The EBV-specific cytotoxic T cell response that is essential in controlling the virus in healthy individuals is suppressed...

Cite
Nijland ML, Kersten MJ, Pals ST, et al. Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct. 2015;2(1):e48doi: 10.1097/TXD.0000000000000557.
Nijland, M. L., Kersten, M. J., Pals, S. T., Bemelman, F. J., & Ten Berge, I. J. (2016). Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplantation direct, 2(1), e48. https://doi.org/10.1097/TXD.0000000000000557
Nijland, Marieke L, et al. "Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management." Transplantation direct vol. 2,1 (2016): e48. doi: https://doi.org/10.1097/TXD.0000000000000557
Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, Ten Berge IJ. Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct. 2015 Dec 15;2(1):e48. doi: 10.1097/TXD.0000000000000557. eCollection 2016 Jan. PMID: 27500242; PMCID: PMC4946499.
Copy Download .nbib Format: NLM
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain.

ClinicoEconomics and outcomes research : CEOR

Casado LF, Burgos A, González-Haba E, Loscertales J, Krivasi T, Orofino J, Rubio-Terres C, Rubio-Rodríguez D.
PMID: 27703384
Clinicoecon Outcomes Res. 2016 Sep 21;8:475-484. doi: 10.2147/CEOR.S114524. eCollection 2016.

OBJECTIVE: To evaluate the cost-effectiveness of obinutuzumab in combination with chlorambucil (GClb) versus rituximab plus chlorambucil (RClb) in the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL) and with comorbidities that make them unsuitable for full-dose fludarabine-based...

Cite
Casado LF, Burgos A, González-Haba E, et al. Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain. Clinicoecon Outcomes Res. 2016;8:475-484doi: 10.2147/CEOR.S114524.
Casado, L. F., Burgos, A., González-Haba, E., Loscertales, J., Krivasi, T., Orofino, J., Rubio-Terres, C., & Rubio-Rodríguez, D. (2016). Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain. ClinicoEconomics and outcomes research : CEOR, 8475-484. https://doi.org/10.2147/CEOR.S114524
Casado, Luis Felipe, et al. "Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain." ClinicoEconomics and outcomes research : CEOR vol. 8 (2016): 475-484. doi: https://doi.org/10.2147/CEOR.S114524
Casado LF, Burgos A, González-Haba E, Loscertales J, Krivasi T, Orofino J, Rubio-Terres C, Rubio-Rodríguez D. Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain. Clinicoecon Outcomes Res. 2016 Sep 21;8:475-484. doi: 10.2147/CEOR.S114524. eCollection 2016. PMID: 27703384; PMCID: PMC5036824.
Copy Download .nbib Format: NLM
Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy.

Case reports in oncology

Musa F, Baidas S.
PMID: 26034479
Case Rep Oncol. 2015 Apr 22;8(1):196-9. doi: 10.1159/000381868. eCollection 2015.

We here describe a patient with an idiopathic thrombotic thrombocytopenic purpura (TTP) secondary to an ADAMTS13 inhibitor that continued to be dependent on plasmapheresis until the patient was treated with rituximab. TTP manifestations subsided with rituximab treatment in spite...

Cite
Musa F, Baidas S. Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy. Case Rep Oncol. 2015;8(1):196-9doi: 10.1159/000381868.
Musa, F., & Baidas, S. (2015). Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy. Case reports in oncology, 8(1), 196-9. https://doi.org/10.1159/000381868
Musa, Faisal, and Baidas, Said. "Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy." Case reports in oncology vol. 8,1 (2015): 196-9. doi: https://doi.org/10.1159/000381868
Musa F, Baidas S. Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy. Case Rep Oncol. 2015 Apr 22;8(1):196-9. doi: 10.1159/000381868. eCollection 2015. PMID: 26034479; PMCID: PMC4448046.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 4411 entries